3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2
1
Phase 1/2
1
Status
Recruiting
4
Completed
4
Sponsor Class
INDUSTRY
4
Study Type
Interventional
4
Sponsor
Cancer Type
Genitourinary
3
Tumor-Agnostic
1
Conditions
Prostatic Neoplasms, Castration-Resistant
1
Prostatic Neoplasms
1
Prostate Cancer Metastatic
1
Neoplasms
1
Interventions
pembrolizumab
241
Carboplatin
167
Injections
138
Paclitaxel
119
Gemcitabine
116
Bevacizumab
112
Cisplatin
105
Docetaxel
82
Cyclophosphamide
78
Pemetrexed
76
Capecitabine
69
Fluorouracil
67
Oxaliplatin
65
Fulvestrant
57
fludarabine
55
Nivolumab
55
Leucovorin
52
Cetuximab
52
130-nm albumin-bound paclitaxel
47
Dexamethasone
46
Rituximab
41
atezolizumab
37
venetoclax
35
Drug Therapy
35
toripalimab
34
enzalutamide
34
Irinotecan
34
durvalumab
32
Prednisone
32
Letrozole
32
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
4 trials
Recent
Start date
Enrollment
Recruiting
×
INDUSTRY
×
fludrocortisone acetate
×
Clear all
NCT06136650
2026-06-03
MK-5684-004
Merck Sharp & Dohme LLC
Phase 3
Recruiting
1,314 enrolled
NCT06353386
2026-05-26
MK-5684-01A
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
220 enrolled
NCT06979596
2026-05-13
OMAHA-015
Merck Sharp & Dohme LLC
Phase 2
Recruiting
250 enrolled
NCT06136624
2026-05-05
OMAHA-003
Merck Sharp & Dohme LLC
Phase 3
Recruiting
1,310 enrolled